Modiblast Pharma

This content was machine translated.

About Modiblast Pharma

Modiblast Pharma is working to enter the clinical development phase with novel dendritic cell therapies for hematologic malignancies. The focus is on the core challenge of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS): the extremely high relapse rate after successful initial therapy. The Modiblast approach (3 patents granted) combines immunomodulators to stimulate blasts (cancer cells) to differentiate into leukemia-specific dendritic cells (DCleu) in the patient (in vivo). This causes both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generate memory cells. Unlike, for example, CAR-T, it is not necessary to identify and select specific target molecules. Furthermore, no complicated and expensive ex vivo cell extraction and preparation procedures or GMP facilities are required. Our long-term goal is to provide an easy-to-use, self-administered medicine that can stabilize remissions or halt disease progression. This therapy can also normalize platelet and neutrophil counts. The next step in clinical development is a phase 1a/2b study that recently passed scientific consultation with the BfArM.

Discover more articles, startups, and events from the ecosystem

Ecosystem

First Into the Ocean, Now Into Space: Isar Aerospace Achieves a Breakthrough

08.09.26

4 Min.

Ecosystem

Startup Meets Craft 2026: Register Now for the Anniversary Edition

08.09.26

2 Min.

Deals

Millions in Funding for Project-S

07.09.26

4 Min.

Conference

Startups for Tomorrow Festival 2026

September 15, 2026

09:00 AM – 07:00 PM

smartvillage Bogenhausen, Munich

Workshop

How to Turn Your Communication into a Strategic Asset

September 15, 2026

10:00 AM – 11:30 AM

gate – Garchinger Technologie- und Gründerzentrum GmbH, Garching bei München

Air2Growth

Air2Growth is developing an innovative system that converts CO2 emissions directly on-site into high-quality organic fertilizer. Using advanced microalgae technology, we create a closed circular economy that enables more sustainable, independent, and economical agriculture. Our solution specifically targets greenhouse operators as well as modern agricultural businesses. By directly utilizing exhaust gases and CO2 sources, our customers not only actively lower their environmental footprint, but also noticeably reduce their ongoing fertilizer costs at the same time. In times of fluctuating market prices and uncertain supply chains, Air2Growth makes businesses independent of fossil raw materials and synthetic imports. In this way, we combine effective climate protection with concrete economic benefits and strengthen the future viability of regional food production.

NeoSoma

At NeoSoma, we empower individuals by restoring full control over their health data. Our open-access tracker ensures that users own their data and decide precisely who may access them – without subscription barriers or vendor lock-in. For research our device provides raw signal output, configurable sampling rates and duty cycles, and full transparency of sensor streams. We believe that health tracking should serve the individual first – your body, your data, your decisions – while offering the same professional-grade foundation for science and discovery.

rnhale

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challenges of pulmonary RNA delivery, stability, deep lung deposition, and cellular uptake, our technology unlocks a more effective path for RNA-based therapies to reach their target. Our goal is to develop effective, locally-acting respiratory therapies that address disease at its molecular source. Our vision: to redefine the treatment of severe lung diseases.